 |
|
|
| |
Response rates are similar for patients with and without advanced fibrosis/cirrhosis, and highest with peginterferon alfa-2a (40KD) 180 μg for 48 weeks in the NEPTUNE study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
M. McKenna,1 Y. Cui,2 S. Thompson,3 C. Wat1 1Roche Products Limited, Welwyn Garden City, UK; 2Shanghai Roche Pharmaceuticals Ltd, Beijing, China; 3Chugai Pharmaceutical Co. Ltd, Tokyo, Japan
|
| |
|
|
|
|
|
